文献速递重症综合管理与镇静镇痛心脑血管急症呼吸衰竭与机械通气

治疗性低温在重症患者中的应用:高质量随机试验的系统评价与Meta分析

Therapeutic Hypothermia in Critically Ill Patients: A Systematic Review and Meta-Analysis of High Quality Randomized Trials.
PubMed 文献 · Crit Care Med · 2020-01-01
一句话结论高质量随机证据显示,在创伤性脑损伤、严重感染和卒中重症患者中,治疗性低温与死亡率升高相关,且不改善神经功能预后。

该系统评价与Meta分析纳入14项低偏倚风险随机试验(共2670例患者),覆盖创伤性脑损伤、严重感染和卒中三种场景,比较治疗性低温(32-35°C,至少24小时)与常规治疗。主要结果显示,低温组最长随访死亡率显著升高(31% vs 25%;RR 1.24;95%CI 1.10-1.39;P=0.0004;I²=0%),而幸存者良好神经功能预后两组无差异(43% vs 46%;RR 1.04;95%CI 0.97-1.12;P=0.27;I²=1%)。低温组心律失常显著增加,肺炎、严重感染、出血、肾衰竭、深静脉血栓和不可控颅内高压无差异。作者结论认为,在国际指南已支持的适应证(成人心脏骤停和新生儿缺氧缺血性脑病)之外,常规应用治疗性低温应避免。

要点

  • 在创伤性脑损伤、严重感染和卒中重症患者中,治疗性低温(32-35°C,至少24小时)与最长随访死亡率升高相关(31% vs 25%;RR 1.24;95%CI 1.10-1.39)。
  • 低温组与常规治疗组幸存者良好神经功能预后无差异(43% vs 46%;RR 1.04;95%CI 0.97-1.12;P=0.27)。
  • 低温组心律失常显著增加,而肺炎、严重感染、出血、肾衰竭、深静脉血栓和不可控颅内高压无差异。
  • 作者结论认为,常规应用治疗性低温应避免用于国际指南适应证(成人心脏骤停和新生儿缺氧缺血性脑病)之外的重症患者。

适用人群与场景

  • 纳入低偏倚风险随机试验中的重症患者,试验场景为创伤性脑损伤、严重感染和卒中。
  • 排除已由国际指南支持的适应证(成人心脏骤停和新生儿缺氧缺血性脑病)以及术中低温的试验。

研究设计与关键结果

  • 研究类型为系统评价与Meta分析,纳入14项低偏倚风险随机试验,共2670例患者,覆盖创伤性脑损伤、严重感染和卒中三种场景。
  • 治疗性低温(32-35°C,至少24小时)与常规治疗相比,最长随访死亡率升高(432/1375 [31%] vs 330/1295 [25%];RR 1.24;95%CI 1.10-1.39;P=0.0004;I²=0%)。
  • 幸存者良好神经功能预后两组无差异(493/1142 [43%] vs 486/1067 [46%];RR 1.04;95%CI 0.97-1.12;P=0.27;I²=1%)。
  • 低温组心律失常显著增加。
  • 肺炎、严重感染、任何感染、出血、肾衰竭、深静脉血栓和不可控颅内高压两组无差异。

证据类型、等级与局限

  • 证据类型为系统评价与Meta分析,仅纳入低偏倚风险随机试验。
  • 异质性:死亡率分析I²=0%,神经功能预后分析I²=1%。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,高质量随机证据表明治疗性低温与死亡率升高相关且不改善神经功能预后,常规应用治疗性低温应避免用于国际指南适应证(成人心脏骤停和新生儿缺氧缺血性脑病)之外的重症患者。
  • 作者指出,尽管特定场景下治疗性低温仍可能有益,但常规应用应避免。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To investigate the effect of the application of therapeutic hypothermia (32-35°C) on survival and major clinical endpoints in critically ill patients.

DATA SOURCES: We searched online database and clinical trial registries dated up to April 30, 2019, and references of relevant studies.

STUDY SELECTION: Low risk of bias randomized trials which compared hypothermia applied for at least 24 hours and conventional therapy in critically ill patients were included. We excluded trials investigating therapeutic hypothermia in indications already supported by international guidelines (adult cardiac arrest and hypoxic-ischemic encephalopathy of newborns) or intraoperative hypothermia.

DATA EXTRACTION: Titles and abstracts were reviewed independently by two authors. If the articles seemed eligible, full-text articles were reviewed, and data were abstracted using a structured template.

DATA SYNTHESIS: Our search retained 14 low risk of bias randomized trials (2,670 patients) performed in three different settings: traumatic brain injury, serious infections, and stroke. Therapeutic hypothermia was associated with an increase in mortality at longest follow-up available (432/1,375 [31%] vs 330/1,295 [25%]; risk ratio, 1.24; 95% CI, 1.10-1.39; p = 0.0004; I = 0%). Pooled results showed no difference of good neurologic outcome among survivors between the two treatment arms (493/1,142 [43%] vs 486/1,067 [46%]; risk ratio, 1.04; 95% CI, 0.97-1.12; p = 0.27; I = 1%). Arrhythmias were significantly increased among patients undergoing therapeutic hypothermia. We found no difference between groups in pneumonia, serious infections, any infection, hemorrhage, renal failure, deep vein thrombosis, and uncontrollable intracranial hypertension.

CONCLUSIONS: High-quality randomized evidence indicates that therapeutic hypothermia is associated with higher mortality and no difference in good neurologic outcome compared with normothermia in critically ill patients. Although there still might be a possibility that therapeutic hypothermia is beneficial in a specific setting, routine application of therapeutic hypothermia would better be avoided outside the settings indicated by international guidelines (adult cardiac arrest and hypoxic-ischemic encephalopathy of newborns).

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Kim JH, Nagy Á, Putzu A, et al. Therapeutic Hypothermia in Critically Ill Patients: A Systematic Review and Meta-Analysis of High Quality Randomized Trials. Crit Care Med. 2020. PMID: 32355134. doi:10.1097/CCM.0000000000004364

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。